Cyteir Therapeutics, Inc. 8-K/A SEC Filings

Filed On	Filing
03 Feb 2023	8-K/A: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +2 more Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy

Comments